Use of GLP-1 Receptor Agonists Linked to Lower Risk for Certain Cancers (Gastroenterology Advisor)

A JAMA Oncology study of over 86,000 patients found that GLP-1 users had reduced overall cancer risk, with particularly lower rates of endometrial, ovarian, and meningioma cancers. Researchers also noted a possible rise in kidney cancer risk, leaving open the question of whether the benefit comes from the drug itself or the weight loss it triggers. Long-term follow-up is needed to understand the full impact.